ArticleAnnals of the rheumatic diseases2022

Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease : a case report.

Brigitte Bader-Meunier et al.PubMed ↗Publisher ↗

No numbers read from the abstract.